ALX Oncology Holdings Inc.
ALXO
$2.19
$0.041.86%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -24.08% | -16.49% | -20.68% | 31.22% | 13.50% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -24.80% | -30.81% | -43.47% | -15.74% | -36.25% |
| Operating Income | 24.80% | 30.81% | 43.47% | 15.74% | 36.25% |
| Income Before Tax | 21.65% | 27.89% | 34.14% | 13.57% | 35.87% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 21.65% | 27.89% | 34.14% | 13.57% | 35.87% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 21.65% | 27.89% | 34.14% | 13.57% | 35.87% |
| EBIT | 24.80% | 30.81% | 43.47% | 15.74% | 36.25% |
| EBITDA | 24.77% | 30.81% | 43.63% | 15.82% | 36.43% |
| EPS Basic | 23.79% | 29.07% | 36.13% | 18.81% | 40.49% |
| Normalized Basic EPS | 23.78% | 29.08% | 43.95% | 18.82% | 40.48% |
| EPS Diluted | 23.79% | 29.07% | 36.13% | 18.81% | 40.49% |
| Normalized Diluted EPS | 23.78% | 29.08% | 43.95% | 18.82% | 40.48% |
| Average Basic Shares Outstanding | 2.80% | 1.68% | 3.11% | 6.46% | 7.77% |
| Average Diluted Shares Outstanding | 2.80% | 1.68% | 3.11% | 6.46% | 7.77% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |